Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation

INTRODUCTION: Met activation by gene amplification and its ligand, hepatocyte growth factor (HGF), imparts resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer. We recently reported that Met activation by HGF stimulates the production of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakade, Junya, Takeuchi, Shinji, Nakagawa, Takayuki, Ishikawa, Daisuke, Sano, Takako, Nanjo, Shigeki, Yamada, Tadaaki, Ebi, Hiromichi, Zhao, Lu, Yasumoto, Kazuo, Matsumoto, Kunio, Yonekura, Kazuhiko, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132034/
https://www.ncbi.nlm.nih.gov/pubmed/24828661
http://dx.doi.org/10.1097/JTO.0000000000000170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132034/
https://www.ncbi.nlm.nih.gov/pubmed/24828661
http://dx.doi.org/10.1097/JTO.0000000000000170

Ejemplares similares